Inventor · disambiguated record
Bruce N. Rogers
Also filed as: ROGERS BRUCE N · ROGERS BRUCE NELSEN · ROGERS BRUCE NELSON
47 granted patents·24 pending applications·589 citations·filing 2000–2024
98Inventor score
Top patents by PatentIndex Score
71 records- 0196US12145935B2Inhibitors of (α-v)(β-6) integrinMORPHIC THERAPEUTIC INC·Filed 2023·Granted Nov 19, 2024·4 cites·20 claims
- 0296US11795167B2Inhibitors of (α-v)(β-6) integrinMORPHIC THERAPEUTIC INC·Filed 2021·Granted Oct 24, 2023·5 cites·19 claims
- 0396US6407092B1Tetracyclic azepinoindole compoundsUPJOHN CO·Filed 2000·Granted Jun 18, 2002·110 cites·38 claims
- 0495US11827621B2Inhibitors of (α-v)(β-6) integrinMORPHIC THERAPEUTIC INC·Filed 2021·Granted Nov 28, 2023·5 cites·9 claims
- 0595US11021480B2Inhibiting (α-V)(β-6) integrinMORPHIC THERAPEUTIC INC·Filed 2020·Granted Jun 1, 2021·8 cites·2 claims
- 0695US6919359B2Azabicyclic-substituted-heteroaryl compounds for the treatment of diseasePFIZER·Filed 2002·Granted Jul 19, 2005·61 cites·23 claims
- 0795US6492385B2Quinuclidine-substituted heteroaryl moieties for treatment of diseaseUPJOHN CO·Filed 2001·Granted Dec 10, 2002·70 cites·97 claims
- 0894US12415796B2Inhibitors of (αv)(β6) integrinMORPHIC THERAPEUTIC INC·Filed 2023·Granted Sep 16, 2025·2 cites·8 claims
- 0994US11739087B2Inhibiting (α-v)(β-6) integrinMORPHIC THERAPEUTIC INC·Filed 2021·Granted Aug 29, 2023·5 cites·9 claims
- 1094US11046669B2Inhibitors of (α-v)(β-6) integrinMORPHIC THERAPEUTIC INC·Filed 2019·Granted Jun 29, 2021·8 cites·35 claims
- 1194US9315520B22-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amidesPFIZER·Filed 2015·Granted Apr 19, 2016·15 cites·26 claims
- 1294US9107923B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2015·Granted Aug 18, 2015·11 cites·30 claims
- 1393US11046685B2Inhibitors of (α-v)(β-6) integrinMORPHIC THERAPEUTIC INC·Filed 2018·Granted Jun 29, 2021·8 cites·42 claims
- 1493US11040955B2Inhibitors of (alpha-v)(beta-6) integrinMORPHIC THERAPEUTIC INC·Filed 2018·Granted Jun 22, 2021·8 cites·59 claims
- 1593US10759756B2Antagonists of human integrin α4β7MORPHIC THERAPEUTIC INC·Filed 2019·Granted Sep 1, 2020·7 cites·42 claims
- 1693US9527831B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2014·Granted Dec 27, 2016·13 cites·30 claims
- 1793US9428523B22-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amidesPFIZER·Filed 2016·Granted Aug 30, 2016·12 cites·37 claims
- 1893US9139561B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2015·Granted Sep 22, 2015·8 cites·30 claims
- 1992US6500840B2Quinuclidine-substituted heteroaryl moieties for treatment of diseaseUPJOHN CO·Filed 2001·Granted Dec 31, 2002·66 cites·52 claims
- 2091US9822097B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2016·Granted Nov 21, 2017·6 cites·15 claims
- 2191US9605007B22-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amidesPFIZER·Filed 2016·Granted Mar 28, 2017·8 cites·6 claims
- 2291US6599916B2Quinuclidine-substituted heteroaryl moieties for treatment of diseaseUPJOHN CO·Filed 2001·Granted Jul 29, 2003·53 cites·52 claims
- 2390US9845301B21,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitorsPFIZER·Filed 2016·Granted Dec 19, 2017·8 cites·9 claims
- 2490US8822494B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2013·Granted Sep 2, 2014·12 cites·54 claims
- 2589US11370773B1Inhibiting human integrin (alpha-4) (beta-7)MORPHIC THERAPEUTIC INC·Filed 2021·Granted Jun 28, 2022·2 cites·24 claims
- 2689US2024317713A1Heteroaromatic compounds and their use as dopamine d1 ligandsPFIZER·Filed 2024·Application pending·0 cites
- 2787US9133190B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2014·Granted Sep 15, 2015·8 cites·60 claims
- 2886US10093655B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2017·Granted Oct 9, 2018·3 cites·20 claims
- 2985US12459942B2Inhibiting (α-v)(β-6) integrinMORPHIC THERAPEUTIC INC·Filed 2024·Granted Nov 4, 2025·0 cites·18 claims
- 3085US12221416B2Antagonists of human integrin α4β7MORPHIC THERAPEUTIC INC·Filed 2023·Granted Feb 11, 2025·0 cites·20 claims
- 3185US10028962B22-amino-6-methy1-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amidesPFIZER·Filed 2017·Granted Jul 24, 2018·3 cites·40 claims
- 3285US6562816B2Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of diseaseUPJOHN CO·Filed 2002·Granted May 13, 2003·26 cites·32 claims
- 3384US10421744B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2018·Granted Sep 24, 2019·2 cites·20 claims
- 3484US2025223289A1Inhibitors of (alpha-v)(beta-6) integrinMORPHIC THERAPEUTIC INC·Filed 2024·Application pending·0 cites
- 3583US11174228B2Antagonists of human integrin (α4)(β7)MORPHIC THERAPEUTIC INC·Filed 2020·Granted Nov 16, 2021·1 cites·20 claims
- 3683US6875762B2Tetracyclic azepinoindole compoundsPFIZER·Filed 2003·Granted Apr 5, 2005·15 cites·28 claims
- 3782US10428034B21,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitorsPFIZER·Filed 2017·Granted Oct 1, 2019·3 cites·18 claims
- 3882US9744173B22-amino 6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amidesPFIZER·Filed 2017·Granted Aug 29, 2017·2 cites·24 claims
- 3982US9527843B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2015·Granted Dec 27, 2016·3 cites·14 claims
- 4081US11104661B1Inhibiting human integrin (α-4) (β-7)MORPHIC THERAPEUTIC INC·Filed 2020·Granted Aug 31, 2021·1 cites·24 claims
- 4177US11964961B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2021·Granted Apr 23, 2024·0 cites·20 claims
- 4274US11014909B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2020·Granted May 25, 2021·0 cites·22 claims
- 4374US10696658B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2019·Granted Jun 30, 2020·0 cites·13 claims
- 4472US6858613B2Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of diseasePFIZER·Filed 2003·Granted Feb 22, 2005·5 cites·5 claims
- 4572US2022340529A1Antagonists of human integrin (alpha4)(beta7)MORPHIC THERAPEUTIC INC·Filed 2021·Application pending·0 cites
- 4671US9868744B2Heteroaromatic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2015·Granted Jan 16, 2018·1 cites·14 claims
- 4768US2020071322A1Inhibiting (alpha-v)(beta-6) integrinMORPHIC THERAPEUTIC INC·Filed 2019·Application pending·0 cites
- 4867US2020354359A1Inhibiting (alpha-v)(beta-6) integrinMORPHIC THERAPEUTIC INC·Filed 2020·Application pending·0 cites
- 4966US10723711B21,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitorsPFIZER·Filed 2019·Granted Jul 28, 2020·0 cites·18 claims
- 5066US9745317B2Heterocyclic compounds and their use as dopamine D1 ligandsPFIZER·Filed 2015·Granted Aug 29, 2017·1 cites·22 claims
Showing the top 50 of 71 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →